SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer
Share this article Share this article LAUSANNE, Switzerland and BOSTON, Feb. 8, 2021 /PRNewswire/ -- SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC). SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer...
Source: prnewswire.com